Collegium Pharmaceutical

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). The Company is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.
Type
Public
HQ
Canton, US
Founded
2002
Size (employees)
234 (est)
Collegium Pharmaceutical was founded in 2002 and is headquartered in Canton, US

Key People at Collegium Pharmaceutical

Michael Heffernan

Michael Heffernan

Co - Founder, President & CEO
Heow Tan

Heow Tan

Vice President of Technical Operations

Collegium Pharmaceutical Office Locations

Collegium Pharmaceutical has an office in Canton
Canton, US (HQ)
800 780 Dedham St

Collegium Pharmaceutical Data and Metrics

Collegium Pharmaceutical Financial Metrics

USD

Net income (Q1, 2017)

(23.1 m)

EBIT (Q1, 2017)

(23.2 m)

Market capitalization (17-Aug-2017)

303.5 m

Cash (31-Mar-2017)

129.6 m
Collegium Pharmaceutical's current market capitalization is $303.5 m.
USDFY, 2015FY, 2016

R&D expense

8 m14.9 m

General and administrative expense

18.9 m80.6 m

Operating expense total

26.9 m95.8 m

EBIT

(26.9 m)(94.1 m)

Interest expense

439 k94 k

Net Income

(27.3 m)(94.2 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

1.6 m3.4 m4.1 m4.3 m3.3 m2.1 m

General and administrative expense

2.9 m5.9 m11.5 m20.2 m23.6 m22.8 m

Operating expense total

4.6 m9.3 m15.6 m24.5 m26.8 m25 m

EBIT

(4.6 m)(9.3 m)(15.6 m)(24.5 m)(26.4 m)(23.2 m)

Interest expense

99 k97 k66 k46 k2 k98 k

Interest income

98 k

Net Income

(4.7 m)(17.7 m)(15.7 m)(24.5 m)(23.1 m)
USDFY, 2015FY, 2016

Cash

95.7 m153.2 m

Accounts Receivable

2.1 m

Inventories

1.2 m1.9 m

Current Assets

96.9 m158.6 m

PP&E

738 k1 m

Total Assets

97.7 m162 m

Accounts Payable

3.5 m9.1 m

Current Liabilities

8.4 m25.6 m

Total Liabilities

27.1 m

Additional Paid-in Capital

214.1 m358.1 m

Retained Earnings

(129 m)(223.2 m)

Total Equity

85.1 m134.9 m

Financial Leverage

1.1 x1.2 x
USDQ3, 2015Q2, 2016Q3, 2016Q1, 2017

Cash

105.5 m110.7 m91 m129.6 m

Accounts Receivable

3 m1.7 m3.3 m

Inventories

1.2 m1.6 m1.5 m

Current Assets

106.3 m116.5 m95.4 m136.5 m

PP&E

627 k676 k772 k1 m

Total Assets

107.1 m119.7 m98.7 m139.8 m

Accounts Payable

3.2 m6.1 m9 m6.8 m

Current Liabilities

8.6 m18.2 m22.2 m24.5 m

Additional Paid-in Capital

213 m267.8 m269.9 m360.6 m

Retained Earnings

(119.5 m)(169.2 m)(195.6 m)(246.3 m)

Total Equity

93.6 m98.7 m74.3 m114.4 m

Financial Leverage

1.1 x1.2 x1.3 x1.2 x
USDFY, 2015FY, 2016

Net Income

(27.3 m)(94.2 m)

Depreciation and Amortization

171 k655 k

Accounts Receivable

(2.1 m)

Inventories

(659 k)(1.3 m)

Accounts Payable

1.3 m5.6 m

Cash From Operating Activities

(21.6 m)(75.1 m)

Purchases of PP&E

(362 k)(477 k)

Cash From Investing Activities

(362 k)(3 m)

Cash From Financing Activities

116 m135.6 m

Interest Paid

353 k284 k
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(4.7 m)(17.7 m)(15.7 m)(24.5 m)(23.1 m)

Depreciation and Amortization

130 k208 k

Accounts Receivable

3 m1.7 m(1.2 m)

Inventories

1.2 m1.6 m(179 k)

Accounts Payable

2.2 m962 k6.2 m6.1 m9 m(2.3 m)

Cash From Operating Activities

(12.6 m)(23.7 m)

Purchases of PP&E

(175 k)(29 k)

Cash From Investing Activities

(175 k)(29 k)

Cash From Financing Activities

116.6 m50 k

Interest Paid

260 k49 k

Income Taxes Paid

4 k
Y, 2017

Financial Leverage

1.2 x

Collegium Pharmaceutical Market Value History

Traffic Overview of Collegium Pharmaceutical

Collegium Pharmaceutical Company Life and Culture

You may also be interested in